Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Cytomegalovirus reactivation in patients with immune-mediated gastritis].
Paredes-Ruiz D, López-López F, Núñez-Sobrino JA, Gómez-Martin C, Díaz-Pedroche C, Lizasoain M. Paredes-Ruiz D, et al. Enferm Infecc Microbiol Clin (Engl Ed). 2023 May;41(5):298-300. doi: 10.1016/j.eimce.2022.03.017. Epub 2023 Jan 19. Enferm Infecc Microbiol Clin (Engl Ed). 2023. PMID: 36681573 Review. Spanish.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study.
Lordick F, Mauer ME, Stocker G, Cella CA, Ben-Aharon I, Piessen G, Wyrwicz L, Al-Haidari G, Fleitas-Kanonnikoff T, Boige V, Obermannová RL, Martens UM, Gomez-Martin C, Thuss-Patience P, Arrazubi V, Avallone A, Shiu KK, Artru P, Brenner B, Sanchez CB, Chau I, Lorenzen S, Daum S, Sinn M, Merelli B, van Grieken NCT, Nilsson M, Collienne M, Giraut A, Smyth E. Lordick F, et al. Among authors: gomez martin c. Ann Oncol. 2024 Nov 12:S0923-7534(24)04906-8. doi: 10.1016/j.annonc.2024.10.829. Online ahead of print. Ann Oncol. 2024. PMID: 39542422 Free article.
Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development.
Massaro C, Sensoy HN, Mulders M, De Schrijver C, Gómez-Martín C, Simon Nieto J, Lagerweij T, Atmopawiro A, Pérez-Boza J, Bebelman M, Bosch L, Foderaro S, Neves Ferreira M, van Eijndhoven MAJ, van Weering JRT, Dell'Aversana C, Altucci L, Savci-Heijink CD, van de Donk NWCJ, Giorgio C, Brandolini L, Allegretti M, Pegtel DM, Baglio SR. Massaro C, et al. Among authors: gomez martin c. Clin Cancer Res. 2024 Oct 15;30(20):4714-4728. doi: 10.1158/1078-0432.CCR-23-4097. Clin Cancer Res. 2024. PMID: 39115426
Full-length tRNAs lacking a functional CCA tail are selectively sorted into the lumen of extracellular vesicles.
Scheepbouwer C, Aparicio-Puerta E, Gómez-Martin C, van Eijndhoven MAJ, Drees EEE, Bosch L, de Jong D, Wurdinger T, Zijlstra JM, Hackenberg M, Gerber A, Pegtel DM. Scheepbouwer C, et al. Among authors: gomez martin c. bioRxiv [Preprint]. 2024 May 12:2024.05.12.593148. doi: 10.1101/2024.05.12.593148. bioRxiv. 2024. PMID: 38765958 Free PMC article. Preprint.
Incidence and causes of hospitalization in patients with transthyretin (ATTR-CA) and light chain (AL-CA) cardiac amyloidosis.
Enríquez-Vázquez D, Gómez-Martín C, Barge-Caballero G, Barge-Caballero E, López-Pérez M, Bilbao-Quesada R, González-Babarro E, Gómez-Otero I, López-López A, Gutiérrez-Feijoo M, Varela-Román A, Crespo-Leiro MG. Enríquez-Vázquez D, et al. Among authors: gomez martin c. Med Clin (Barc). 2024 Apr 12;162(7):e1-e7. doi: 10.1016/j.medcli.2024.01.005. Epub 2024 Feb 28. Med Clin (Barc). 2024. PMID: 38423944 English, Spanish.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
70 results